Neuroanaesthesia & neurocritical care
Erector Spinae Plane Block in Multimodal Analgesia After Lumbar Spinal Fusion Surgery: A Blinded Randomized Placebo-Controlled Trial
Authors' conclusion
Bilateral ESPB with ropivacaine did not reduce early postoperative pain or opioid use in patients undergoing lumbar spinal fusion.
Study context
- Population
- Patients undergoing elective lumbar spinal fusion
- Participants
- 76 patients
- Comparison
- Bilateral Erector Spinae Plane Block (ESPB) with ropivacaine vs placebo after surgery
- Primary endpoint
- Pain intensity (Numeric Rating Scale (NRS))
- Follow-up
- 1 hour postanesthesia
Methodological detailssingle-centre, blinded, placebo-controlled
- Single-centre
- Blinded
- Placebo-controlled
Primary result
As reported in the abstract
Ropivacaine
3.8
mean · SD 3
Placebo
4. 2
mean · SD 2.6
P = 0.56
Secondary outcomes
Opioid use · 30 days
| Outcome | Ropivacaine | Placebo |
|---|---|---|
| Pain intensity (NRS) · 30 days | — not stated in the abstract | mean 3. 6 ± 2.5 |
— not stated in the abstract
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Erector Spinae Plane Block in Multimodal Analgesia After Lumbar Spinal Fusion Surgery: A Blinded Randomized Placebo-Controlled Trial. Anesth Analg. Published 2 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →